Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Necrotizing Enterocolitis Market Size Shifted, And What Is the Outlook Through 2034?

Robust growth has been witnessed in the necrotizing enterocolitis market in the past few years. Its size is projected to escalate from $4.83 billion in 2024 to approximately $5.14 billion in 2025, boasting a compound annual growth rate (CAGR) of 6.5%. This expansion in the previous period is linked to factors such as an upsurge in the number of necrotizing enterocolitis cases, population growth, enhanced per capita income, increased allocations of government funding, as well as a surge in instances of premature births.

The market for necrotizing enterocolitis is predicted to experience substantial growth in the upcoming years, escalating to a value of$6.56 billion in 2029 with a compound annual growth rate (CAGR) of 6.3%. Factors contributing to this projected growth during the forecast period include the increasing healthcare costs, the rate of occurrence and prevalence of ulcerative colitis (UC), a surge in gastrointestinal diseases, a rise in the population of the elderly and those fighting obesity, and a growing population of the elderly. Key trends forecasted to shape the market include progress in biomarker research to detect NEC early, advances in non-invasive testing methods, the adoption of state-of-the-art monitoring systems, breakthroughs in surgical techniques, and the progression of targeted therapies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22068&type=smp

What are the Fundamental Drivers and Innovations Shaping the Necrotizing Enterocolitis Market?

The surge in premature birth instances is anticipated to drive the necrotizing enterocolitis market’s expansion. Preterm births, another term for premature births, occur when a baby is delivered before 37 weeks of gestation, compared to the conventional 40-week pregnancy duration. The rise in premature births can be attributed to various maternal health issues such as hypertension, diabetes, infections, and lifestyle choices such as smoking, drug abuse, and inadequate nutrition. These factors heighten the risk of preterm labor, leading to an increased incidence of premature births. Subsequently, more premature births result in an increased occurrence of necrotizing enterocolitis (NEC), as preterm babies’ gastrointestinal systems are underdeveloped and more prone to inflammation and infection. For example, in January 2024, the Centers for Disease Control and Prevention, a government agency based in the US, reported that premature births make up 8.67% of total annual births in the country. As such, the escalating cases of premature births are propelling the growth of the necrotizing enterocolitis market.

How Is the Necrotizing Enterocolitis Market Segmented?

The necrotizing enterocolitismarket covered in this report is segmented –

1) By Treatment: Total Parenteral Nutrition (TPN); Gastrointestinal Decompression; Antimicrobial Therapy; Antifungal Treatment; Paracentesis; Other Treatments

2) By Diagnosis: Laboratory Tests; Imaging Techniques

3) By Stage: Stage I (Suspected Necrotizing Enterocolitis); Stage II (Definite Necrotizing Enterocolitis); Stage III (Advanced Necrotizing Enterocolitis)

4) By Distribution Channel: Direct Tender; Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels

5) By End-User: Hospitals; Neonatal Intensive Care Units (NICUs); Specialty Clinics

Subsegments:

1) By Total Parenteral Nutrition (TPN): Standard TPN Formulations; Customized Or Individualized TPN Solutions; Lipid Emulsions for TPN; Protein And Amino Acid Supplements In TPN; Micronutrient And Electrolyte-Enhanced TPN

2) By Gastrointestinal Decompression: Nasogastric Tube (NG Tube) Decompression; Orogastric Tube Decompression; Surgical Gastrostomy for Decompression; Non-Surgical Decompression Techniques

3) By Antimicrobial Therapy: Broad-Spectrum Antibiotics; Gram-Positive Coverage Antibiotics; Gram-Negative Coverage Antibiotics; Combination Antibiotic Therapy; Prophylactic Antibiotic Strategies For High-Risk Neonates

4) By Antifungal Treatment: Systemic Antifungal Therapy; Prophylactic Antifungal Therapy For Preterm Infants; Combination Antifungal And Antibiotic Therapy For Severe NEC

5) By Paracentesis: Diagnostic Paracentesis; Therapeutic Paracentesis; Guided Paracentesis using Ultrasound Or Radiological Techniques

6) By Other Treatments: Probiotics And Prebiotics for NEC Prevention; Surgical Interventions; Stem Cell Therapy And Regenerative Medicine Approaches; Immunomodulatory Therapies; Supportive Care

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=22068&type=smp

Which Regions Are Driving the Next Phase of the Necrotizing Enterocolitis Market Growth?

North America was the largest region in the necrotizing enterocolitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the necrotizing enterocolitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Trends Are Shaping the Future of the Necrotizing Enterocolitis Market?

Primary businesses in the necrotizing enterocolitis market are concentrating their efforts on creating innovative treatment options, like cell-free sterile biologic remedies, to fill the substantial gap in sufficient treatments and enhance results for premature babies. Cell-free sterile biologic solutions are clean, refined liquids filled with bioactive molecules like proteins, growth stimulants, and cytokines, which originate from cultured cells, but do not contain any intact cells, their objective is to facilitate healing and lower inflammation. In December 2023, for example, the U.S.-based biopharmaceutical firm, Noveome Biotherapeutics, Inc., was greenlit by the U.S. Food and Drug Administration (FDA) to proceed with Phase 1-2 clinical trials for ST266, an innovative biologic designed for necrotizing enterocolitis (NEC) treatment in premature infants. The approval of ST266 is a significant juncture as it is likely to represent the foremost major therapeutic progress for NEC in over 30 years. This addresses a severe health necessity considering the disease’s elevated rates of sickness and death among susceptible groups.

View the full report here:

https://www.thebusinessresearchcompany.com/report/necrotizing-enterocolitis-global-market-report

How Is the Necrotizing Enterocolitis Market Defined and What Are Its Core Parameters?

Necrotizing enterocolitis (NEC) is a serious, potentially life-threatening gastrointestinal condition that primarily affects premature infants. It involves the inflammation and death (necrosis) of the tissue in the intestines, which can lead to perforation, infection, and other complications. The common symptoms of necrotizing enterocolitis include feeding intolerance, abdominal distension, vomiting, and changes in bowel movements.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22068

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model